Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center
Keywords/Phrases:  leukemia
Results 1-25 of 981 for your search:
Start Over
Laboratory-Treated T Cells in Treating Patients with High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated with Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2498.00, NCI-2011-03362, 2498, NCT01640301
Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IMGN779 0601, NCI-2016-00258, NCT02674763
Abatacept, Cyclosprine, Tacrolimus, and Methotrexate in Preventing Graft-versus-Host Disease in Patients with High-Risk Leukemia Undergoing Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Supportive care
Age: 6 and over
Trial IDs: 2692.00, NCI-2016-00220, PBMTC PROTOCOL GVH 1201, NCT01743131
Eltrombopag Olamine in Treating Thrombocytopenia in Patients with Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
Status: Active
Phase: Phase III, Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 2011-0319, NCI-2011-03336, NCT01428635
Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 1 to 21
Trial IDs: AALL06B1, NCI-2009-00314, CDR0000496763, COG-AALL06B1, NCT00896766
Autologous CD19-Specific T Cells in Treating Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-114, NCI-2010-00255, NCT01044069
AC220 With 5-Aza or Low Dose Cytarabine
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: 2012-1047, NCI-2013-02274, P50CA100632, NCT01892371
Microtransplantation in Treating Younger Patients with Refractory or Relapsed Hematological Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: MITREL, NCI-2015-00691, NCT02433483
Partially Matched Donor Stem Cell and Umbilical Cord Blood Transplant Using a Reduced Intensity Preparative Regimen in Treating Younger Patients with Hematological Malignancies
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: HAPCORD, NCI-2014-00526, NCT02199041
Donor Umbilical Cord Blood Transplant After Combination Chemotherapy and Total-Body Irradiation in Treating Younger Patients With High-Risk Hematologic Malignancies
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: UCBT01, NCI-2011-03700, NCT01328496
Sirolimus or Vorinostat in Combination with Hydroxychloroquine in Treating Patients with Advanced or Metastatic Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0588, NCI-2011-00303, NCT01266057
Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: KX02-01-13, NCI-2015-00135, NCT02326441
Cyclophosphamide in Preventing Graft-versus-Host Disease after Donor Stem Cell Transplant in Patients with Hematopoietic Malignancies
Status: Active
Phase: Phase II
Type: Supportive care
Age: 19 to 65
Trial IDs: UAB1286, NCI-2015-00251, NCT02065154
[F-18] FLT PET in Measuring Tumor Response in Patients with Solid Tumors or Hematopoietic Cancer
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: 2006-127, NCI-2015-01345, 0905007082, NCI-2015-01231, WSU-2006-127, PFIZER-WSU-2006-127, NCT00935090
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 to 75
Trial IDs: OSU-13219, NCI-2014-00763, 2014C0014, NCT02122081
Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: Children and adults
Trial IDs: ABTR02B1, NCI-2009-00325, CDR0000271322, COG-ABTR02B1, NCT01005277
Selinexor in Treating Younger Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 months to 21 years
Trial IDs: 13-563, NCI-2014-00936, KPT330, NCT02091245
Combination Chemotherapy in Treating Patients with Recurrent Acute Myeloid Leukemia or Recurrent Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 64
Trial IDs: 2012-1064, NCI-2013-00548, NCT01794702
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 69
Trial IDs: 7195, NCI-2012-01084, CA180-392, NCT01620216
Cyclophosphamide in Preventing GVHD in Patients with Abnormal Kidney Function Undergoing Donor Stem Cell Transplant
Status: Active
Phase: No phase specified
Type: Natural history/Epidemiology, Supportive care
Age: 18 and over
Trial IDs: 14-273, NCI-2015-00266, NCT02360111
Gemtuzumab Ozogamicin in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, or Chronic Myelogenous Leukemia
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 months and over
Trial IDs: CCCWFU# 99213, NCI-2013-00965, NCT01869803
Ruxolitinib Phosphate in Treating Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10262, NCI-2014-00633, NCT02092324
Studying DNA in Blood and Bone Marrow Samples from Younger Patients with Acute Myeloid Leukemia
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 30 and under
Trial IDs: AAML10B11, NCI-2011-02202, CDR0000660540, COG-AAML10B11, NCT01024127
Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: Not specified
Trial IDs: CCCWFU 99113, NCI-2013-00964, NCT01869777
Start Over